Stockreport

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the...

Dogwood Therapeutics, Inc.  (DWTX) 
PDF funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- SP16 has demonstrated both anti-inflammatory and neural [Read more]